The Business of Healthcare Innovation PDF Download

Author: Lawton Robert Burns
Publisher: Cambridge University Press
ISBN: 9781139445887
Category : Business & Economics
Languages : en
Pages : 408

View

Book Description
The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants.

Author: Greg N. Gregoriou
Publisher: Elsevier
ISBN: 0080466079
Category : Business & Economics
Languages : en
Pages : 433

View

Book Description
Until recently, only the United States had an active venture capital market. This is changing rapidly, as many other countries have experienced rapid growth in venture capital financing over the past five years. This book contains new scientific articles showcasing the latest research on venture capital in Europe. Venture capital investment remains a hot topic with portfolio managers, individual investors, academics worldwide. This book examines in detail all the major issues regarding venture capital investment: contracting, financing, regulation, valuation, etc. and identifies new trends in the venture capital arena. Features a foreword by Josh Lerner.*The only book in which academics from around the world present the latest research on venture capital in Europe*Covers all of Europe as well as including overview papers about venture capital industry, public and private venture capital, valuation, financing, contracting, structuring, regulation, etc. *Comprehensive, authoritative coverage

Author: Eileen Appelbaum
Publisher: Russell Sage Foundation
ISBN: 1610448189
Category : Business & Economics
Languages : en
Pages : 396

View

Book Description
Private equity firms have long been at the center of public debates on the impact of the financial sector on Main Street companies. Are these firms financial innovators that save failing businesses or financial predators that bankrupt otherwise healthy companies and destroy jobs? The first comprehensive examination of this topic, Private Equity at Work provides a detailed yet accessible guide to this controversial business model. Economist Eileen Appelbaum and Professor Rosemary Batt carefully evaluate the evidence—including original case studies and interviews, legal documents, bankruptcy proceedings, media coverage, and existing academic scholarship—to demonstrate the effects of private equity on American businesses and workers. They document that while private equity firms have had positive effects on the operations and growth of small and mid-sized companies and in turning around failing companies, the interventions of private equity more often than not lead to significant negative consequences for many businesses and workers. Prior research on private equity has focused almost exclusively on the financial performance of private equity funds and the returns to their investors. Private Equity at Work provides a new roadmap to the largely hidden internal operations of these firms, showing how their business strategies disproportionately benefit the partners in private equity firms at the expense of other stakeholders and taxpayers. In the 1980s, leveraged buyouts by private equity firms saw high returns and were widely considered the solution to corporate wastefulness and mismanagement. And since 2000, nearly 11,500 companies—representing almost 8 million employees—have been purchased by private equity firms. As their role in the economy has increased, they have come under fire from labor unions and community advocates who argue that the proliferation of leveraged buyouts destroys jobs, causes wages to stagnate, saddles otherwise healthy companies with debt, and leads to subsidies from taxpayers. Appelbaum and Batt show that private equity firms’ financial strategies are designed to extract maximum value from the companies they buy and sell, often to the detriment of those companies and their employees and suppliers. Their risky decisions include buying companies and extracting dividends by loading them with high levels of debt and selling assets. These actions often lead to financial distress and a disproportionate focus on cost-cutting, outsourcing, and wage and benefit losses for workers, especially if they are unionized. Because the law views private equity firms as investors rather than employers, private equity owners are not held accountable for their actions in ways that public corporations are. And their actions are not transparent because private equity owned companies are not regulated by the Securities and Exchange Commission. Thus, any debts or costs of bankruptcy incurred fall on businesses owned by private equity and their workers, not the private equity firms that govern them. For employees this often means loss of jobs, health and pension benefits, and retirement income. Appelbaum and Batt conclude with a set of policy recommendations intended to curb the negative effects of private equity while preserving its constructive role in the economy. These include policies to improve transparency and accountability, as well as changes that would reduce the excessive use of financial engineering strategies by firms. A groundbreaking analysis of a hotly contested business model, Private Equity at Work provides an unprecedented analysis of the little-understood inner workings of private equity and of the effects of leveraged buyouts on American companies and workers. This important new work will be a valuable resource for scholars, policymakers, and the informed public alike.

Author: David Shaywitz
Publisher: Createspace Independent Pub
ISBN: 9781492771012
Category : Business & Economics
Languages : en
Pages : 388

View

Book Description
Book Overview1. Entrepreneurs and Startups2. Doctors, Nurses, and Health Professionals3. Pharma, Biotech, Device Companies4. Patients and Consumers5. Employers, Insurers, Regulators6. Gadgets, Apps, Technology7. Behavior, Design, and Translation8. Big Data, Measurement, and Metrics9. VCs and Other Investors10. Innovation---Health matters.“When you have your health, you have everything,” wrote memoirist Augusten Burroughs. “When you do not have your health, nothing else matters at all.”Health can also be very expensive, and reducing costs isn't easy, since as Stanford health policy expert Victor Fuchs famously observed, “Every dollar of waste is income to some individual or organization.”One key challenge healthcare faces today is figuring out how to maintain health and deliver better care for patients while somehow keeping in check the overall costs associated with these activities.The good news is that there is now the massive potential for healthcare transformation. Data-driven analysis has called into question many traditional healthcare assumptions, and permits us to view the challenges in a fresh light. For instance, there seems to be little correlation between healthcare cost and quality—and great care can be delivered at lower cost if we can improve the alignment of incentives among patients, payers, and providers.Key drivers of healthcare change are the intense economic pressure of healthcare costs, the impact—to be determined—associated with the implementation of the Affordable Care Act, and the advent of inexpensive and widely accessible technologies; together these have created a platform for industry transformation the likes of which has not been seen since the dawn of modern surgery.And it's about time. Technology has been used to optimize and redefine virtually every key industry except healthcare. Manufacturing has gone from human assembly lines to robotics; banking has gone from tellers to home banking; travel has gone from agents with brochures to Travelocity; and yet the practice of medicine, in many ways, hasn't changed in decades.Many of today's most passionate entrepreneurs are trying to bring the dazzle and real promise of technology innovation to the challenges of healthcare, resulting in an explosion of companies focused on everything from wearable sensors and weight-loss apps to big data analytics and GPS-tagged hospital equipment—the “internet of things.”These emerging tools and promising technologies—which collectively comprise “digital health”—offer a promising path forward, and entrepreneurs and innovators are forging forward seeking to make a real difference in a field which we all need but which is sorely in need of its own tender loving care if it is to flourish in tomorrow's world.As Hippocrates once said, “Healing is a matter of time, but it is sometimes also a matter of opportunity.” And technology—if judiciously applied—may be just the tonic to help reinvigorate the health of our healthcare industry.The key challenge faced by would-be disruptive technologists is not only recognizing potentially useful analogs from other industries, but also understanding the ways in which health remains fundamentally different.Amid the clamor to disrupt healthcare, we should also take care to preserve and augment what may be right about medicine—the doctor/patient relationship for example, or the drive of inquisitive physicians, especially within academic centers, to continuously push and challenge the limits of what is known and what is possible.In Tech Tonics—a distillation of our writing and thinking over the last several years—we introduce the reader to the fascinating digital health space, including a ground-level view of the landscape, the structural challenges, the players, and the progress.

Author: Les Funtleyder
Publisher: McGraw Hill Professional
ISBN: 0071642951
Category : Business & Economics
Languages : en
Pages : 289

View

Book Description
Is your portfolio in peak health? Ranking among the world's largest markets, the $2.5 trillion health care industry is growing at an unprecedented rate. According to Miller Tabak + Co.'s health care strategist Les Funtleyder, major structural renovations to the system are imminent. “Health care is entering an era of reform,” Funtleyder writes, “and with reform comes change and the opportunity for investment gain.” Health-Care Investing provides a thorough explanation of how the industry's mammoth size and complexity can be worked to your advantage and why health care is more resistant to changes in economic cycles than other markets. Funtleyder gives you a comprehensive overview of the industry, from both macro and micro points of view, so you can make informed decisions regarding your investments. You'll find critical information concerning The natural inelasticity of health care and how to profit from it How to take advantage of the market's complexities and inefficiencies Issues and policy changes you need to know The social responsibility aspect of investing in health care Why this market is essential for diversified portfolios In Health-Care Investing, Funtleyder provides the tools you need to dig up the richest opportunities possible and build them into your investment strategy. You'll get a detailed look at traditional market patterns and the events that have shaped--and will continue to shape--the industry. Then you'll find specific strategies you can use to maximize your profits, whether you invest in pharma, biotech, managed services, or a combination of them. This informative and practical guide also includes a list of questions you can use as an investment “template,” which will help guide your decision-making process. With Health Care Investing, you'll be armed with the know-how to make the right decisions today in order to fully capitalize on events of the future.

Author:
Publisher:
ISBN: 9780787635015
Category : Business consultants
Languages : en
Pages : 1400

View

Book Description

Author: Collectif
Publisher: OECD
ISBN: 9264279946
Category : Business & Economics
Languages : fr
Pages : 228

View

Book Description
The publication is produced by the OECD-Eurostat Entrepreneurship Indicators Programme based on official statistics. The 2017 edition features a new trends chapter, which also introduces recent developments related to the emergence of the "gig economy" and the use of digital tools by micro-enterprises.

Author: Douglas Cumming
Publisher: Oxford University Press
ISBN: 0199942617
Category : Business & Economics
Languages : en
Pages : 1126

View

Book Description
Venture capital (VC) refers to investments provided to early-stage, innovative, and high growth start-up companies. A common characteristic of all venture capital investments is that investee companies do not have cash flows to pay interest on debt or dividends on equity. Rather, investments are made with a view towards capital gain on exit. The most sought after exit routes are an initial public offering (IPO), where a company lists on a stock exchange for the first time, and an acquisition exit (trade sale), where the company is sold in entirety to another company. However, VCs often exit their investments by secondary sales, wherein the entrepreneur retains his or her share but the VC sells to another company or investor buybacks, where the entrepreneur repurchases the VC`s interest and write-offs (liquidations). The Oxford Handbook of Venture Capital provides a comprehensive picture of all the issues dealing with the structure, governance, and performance of venture capital from a global perspective. The handbook comprises contributions from 55 authors currently based in 12 different countries.

Author: John Carreyrou
Publisher: Vintage
ISBN: 1524731668
Category : Business & Economics
Languages : en
Pages : 354

View

Book Description
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close. “Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.

Author:
Publisher:
ISBN:
Category : Corporations
Languages : en
Pages : 1714

View

Book Description
This multi-volume directory which lists more than 40,000 companies is indexed by company name, geographic area, non-U.S. parent companies, technology, product code, CorpTech code, and SIC code. Profiles are provided for each company listed, and company rankings given under each industry.